Arbuckle Stuart A 4

What Happened
Stuart A. Arbuckle, a director of Praxis Precision Medicines (PRAX), received equity awards on February 6, 2026: 688 restricted stock units (RSUs), 478 RSUs, and 224 shares tied to an option/award — a total of 1,390 award units. All items were reported as acquired at $0 (compensation grants rather than cash purchases). The RSUs settle only by delivery of common stock; the 224-share award is a derivative with a short monthly vesting schedule.

Key Details

• Transaction date: February 6, 2026; filing date: February 10, 2026 (timely).
• Reported price: $0 for all awards (compensation grants).
• Total units granted: 1,390 (688 RSUs + 478 RSUs + 224 derivative/option units).
• Vesting highlights:
  • 688 RSUs: vest in two equal annual installments on the first two anniversaries of January 8, 2026 (Jan 8, 2027 and Jan 8, 2028).
  • 478 RSUs: single annual installment on the earlier of June 26, 2026 or the 2026 annual meeting.
  • 224 derivative shares: vest in equal monthly installments on the 26th of each month from Feb 26, 2026 through the earlier of June 26, 2026 or the 2026 annual meeting.
• Shares owned after the transaction: not specified in the provided excerpt.
• Filing timeliness: Filed within the Form 4 deadline (no late filing flag).

Context
These awards are typical compensation grants (RSUs and a short-term vesting award) and do not involve an open-market purchase or sale. RSUs convert into shares when they vest and are normally used to retain or incentivize executives/directors. Such grants are informational about compensation but are not, by themselves, a direct bullish or bearish trading signal.